Physician

Olga Izotova, M.D.

According to 2025 Medicare claims, Olga Izotova, M.D. (NPI: 1528272754) practices endocrinology in the Pinehurst-Southern Pines, NC market, with the plurality of this provider's patient population coming from Moore, NC. This provider's primary affiliated billing organization is PINEHURST MEDICAL CLINIC, INC. (NPI: 1255388369; TIN: 560942980) and primary practice location at 28387-4561. Izotova is affiliated with the agilon health Mid-Atlantic ACO, Inc. (DBA: Senior Health Connect ACO 5) (ACO ID: D0156), participating under the REACH model.

Izotova's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 586 traditional Medicare patients, billed 16,550 HCPCS/CPT codes, and received $342,549 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 5,725 prescription claims across 705 beneficiaries totaling $2,241,655 in drug costs, led by Ozempic (Semaglutide). DME data shows 530 claims. Open Payments data shows 99 records totaling $1,814. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $524,116 to $342,549. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, reported payments moved from a lower plateau to a higher plateau, from $40,605 to $127,880.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,048	22,367	$524,116
2016	1,113	24,296	$532,604
2017	1,026	20,774	$426,740
2018	961	22,224	$414,323
2019	991	20,808	$384,578
2020	850	21,347	$368,152
2021	840	21,296	$379,524
2022	608	17,612	$334,944
2023	583	17,850	$340,057
2024	586	16,550	$342,549

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	642	5,227	$976,898
2016	701	5,912	$1,610,760
2017	774	7,401	$2,365,513
2018	731	6,938	$2,724,622
2019	682	5,425	$2,923,541
2020	658	5,302	$3,773,426
2021	650	5,190	$2,682,973
2022	640	5,115	$2,248,912
2023	668	5,422	$2,499,118
2024	705	5,725	$2,241,655

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	295	722	$58,487
2016	283	704	$52,026
2017	267	711	$99,395
2018	249	771	$132,547
2019	242	882	$164,195
2020	191	808	$163,911
2021	182	745	$146,700
2022	175	632	$135,663
2023	134	668	$141,682
2024	136	530	$147,624

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	344	505	$85
84481	Thyroid hormone, t3 measurement, free	326	506	$16
84443	Blood test, thyroid stimulating hormone (tsh)	327	515	$16
84439	Thyroxine (thyroid chemical), free	331	519	$9
36415	Insertion of needle into vein for collection of blood sample	338	575	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	233	10,847	$344,388
Jardiance	Empagliflozin	342	17,468	$327,705
Korlym	Mifepristone	11	330	$226,099
Mounjaro	Tirzepatide	177	5,597	$205,357
Trulicity	Dulaglutide	110	4,938	$167,386

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	42	203	$81,947
J1817	Insulin for administration through dme (i.e., insulin pump) per 50 units	N	15	48	$19,842
A4238	Supply allowance for adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	40	$13,530
A4224	Supplies for maintenance of insulin infusion catheter, per week	N	19	56	$12,934
E0784	External ambulatory infusion pump, insulin	Y	N/R	35	$11,180

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	99	$1,814	Lilly USA, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Olga Izotova, M.D.?

Tedicare shows public-source Medicare data for Olga Izotova, M.D. (NPI 1528272754), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Olga Izotova, M.D. have ACO affiliation data?

Olga Izotova, M.D. is shown with ACO affiliation data for agilon health Mid-Atlantic ACO, Inc. (DBA: Senior Health Connect ACO 5) (REACH, ACO ID D0156).

What billing organization is linked to Olga Izotova, M.D.?

Olga Izotova, M.D. is linked to PINEHURST MEDICAL CLINIC, INC. (billing NPI 1255388369) in the available physician profile data.

Does Olga Izotova, M.D. have Open Payments data?

Olga Izotova, M.D. has 99 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.